Featured Research Search Results
Treating Advanced MSI-High or dMMR Cancers Using the Targeted Therapy MOMA-341 Given Alone or In Combination with Standard Therapies
Clinicaltrials.gov identifier:
NCT06974110
Treatment
Treatment study for people with advanced or metastatic cancers
Using a Shorter Type of MRI as a Screening Tool for People at High Risk for Prostate Cancer
Clinicaltrials.gov identifier:
NCT05384535
Prevention
Screening for people at high risk for prostate cancer
Pfizer Clinical Trials for Metastatic Prostate Cancer are Now Enrolling
Treatment
Men aged 18 years or older with metastatic prostate cancer
Post-surgery Immunotherapy (Toripalimab) for MMR-D / MSI-H Stage IIB-III Colon Cancer
Clinicaltrials.gov identifier:
NCT07140679
Treatment
Study for people who have had surgery to remove the Stage IIB-III MMR-D / MSI-H colon cancer
Pancreatic Cancer Screening Study (CAPS5)
Clinicaltrials.gov identifier:
NCT02000089
Prevention
Screening study for people at high risk for pancreatic cancer
Registry for People at Increased Risk for Pancreatic Cancer
Clinicaltrials.gov identifier:
NCT06151223
Surveys, Registries, Interviews
Study collecting blood samples and imaging records of people at high risk of developing pancreatic cancer
Study of the Drug Olvi-Vec in Women with Ovarian Cancer
Clinicaltrials.gov identifier:
NCT05281471
Treatment
Treatment for women diagnosed with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer or whose cancer did not respond to prior chemotherapy
Understanding Risk Factors for Stomach Cancer in People with Inherited Mutations
Surveys, Registries, Interviews
Online survey on stomach cancer risk for people with an inherited mutation in genes that are linked to an increased risk of certain cancers
Understanding the Emotional and Social Experiences of Individuals Diagnosed with Ovarian Cancer
Surveys, Registries, Interviews
Survey for people diagnosed with ovarian cancer
PATROL Study: Prostate Cancer Screening for People AT Genetic Risk FOr Aggressive Disease
Clinicaltrials.gov identifier:
NCT04472338
Prevention
Screening study for people with a mutation linked to prostate cancer risk
Understanding the Cancer Journey: A Survey of Patient Experiences and Emotional Impact
Surveys, Registries, Interviews
Online survey for people diagnosed with breast, colorectal, gastric or prostate cancer within the past twenty years
The DETECT Study: Detecting Endometrial Cancer in Tampons
Clinicaltrials.gov identifier:
NCT03538665
Prevention
Early detection of endometrial cancer in women undergoing hysterectomy surgery at the University of Alabama
Effectiveness of Lymph Node Mapping to Reduce the Risk of Swelling in the Legs in Patients with Stage I Endometrial Cancer
Clinicaltrials.gov identifier:
NCT05646316
Treatment
People with stage I endometrial cancer who are having a hysterectomy
Registry to Discover New Treatments and Developmental Processes of Colorectal and Endometrial Cancer in Patients with Hereditary Cancer
Clinicaltrials.gov identifier:
NCT06096688
Surveys, Registries, Interviews
Registry for people who screen for colorectal endometrial cancer
The Phoenix Trial: Cemiplimab for Patients with Localized dMMR Colon Cancer
Clinicaltrials.gov identifier:
NCT05961709
Treatment
Treatment study for people with localized colon cancer who have dMMR
Screening Study for Men at High Genetic Risk for Prostate Cancer
Clinicaltrials.gov identifier:
NCT03805919
Prevention
Prostate screening with MRI for men with Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) or a BRCA1, BRCA2, HOXB13, ATM, NBN, TP53, BRIP1, CHEK2, PALB2, RAD51C, RAD51D, or other mutation
Using ctDNA for Earlier Detection and Treatment of Recurrence or Spread after Treatment for Stage 3 Colon Cancer
Clinicaltrials.gov identifier:
NCT03803553
Treatment
Monitoring and treatment study for people who completed treatment for stage 3 colon cancer
Treatment of HER2-positive Colorectal Cancer as First Line Treatment in the Metastatic Setting
Clinicaltrials.gov identifier:
NCT05253651
Treatment
People with HER2-positive colorectal cancer who have not yet received treatment in the metastatic setting